METTL3

Across TCGA pan-cancer cohorts, METTL3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated METTL3 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher METTL3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated METTL3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where METTL3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.534	0.279	<.001	70	view →
HNSC	DFS	Tertile	IV	0.641	0.987	.006	18	view →
LSCC	DFS	Median	III,IV	0.626	0.944	.027	4	view →
GBM	DFS	Tertile	All	0.513	0.293	.014	2	view →
LUAD	DFS	Median	III,IV	0.314	0.693	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

METTL3–PDAC (DFS)

Open the PDAC breakdown →